Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gun Ho Jang

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Nature Communications|October 8, 2022
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinomaJames T Topham, Erica S Tsang, Joanna M Karasinska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic CancerJennifer J Knox, Grainne O'Kane, Daniel King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic CancerJennifer J Knox, Grainne O'Kane, Daniel King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic CancerYifan Wang, Jin Yong Patrick Park, Alain Pacis, et al.
JAMA Oncology|October 22, 2016
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal AdenocarcinomaAshton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Nature Genetics|February 14, 2020
Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionMichelle Chan-Seng-Yue, Jaeseung C Kim, Gavin W Wilson, et al.
Nature Communications|July 2, 2025
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trialJennifer J Knox, Gun Ho Jang, Robert C Grant, et al.
Nature Genetics|January 15, 2020
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionMichelle Chan-Seng-Yue, Jaeseung C Kim, Gavin W Wilson, et al.
Cancer Cell|January 29, 2019
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in MetastasesAshton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Nature|November 17, 2016
Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patternsFaiyaz Notta, Michelle Chan-Seng-Yue, Mathieu Lemire, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Nature Communications|October 8, 2022
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinomaJames T Topham, Erica S Tsang, Joanna M Karasinska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2025
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic CancerJennifer J Knox, Grainne O'Kane, Daniel King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic CancerJennifer J Knox, Grainne O'Kane, Daniel King, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic CancerYifan Wang, Jin Yong Patrick Park, Alain Pacis, et al.
JAMA Oncology|October 22, 2016
Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal AdenocarcinomaAshton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Nature Genetics|February 14, 2020
Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionMichelle Chan-Seng-Yue, Jaeseung C Kim, Gavin W Wilson, et al.
Nature Communications|July 2, 2025
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trialJennifer J Knox, Gun Ho Jang, Robert C Grant, et al.
Nature Genetics|January 15, 2020
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolutionMichelle Chan-Seng-Yue, Jaeseung C Kim, Gavin W Wilson, et al.
Cancer Cell|January 29, 2019
Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in MetastasesAshton A Connor, Robert E Denroche, Gun Ho Jang, et al.
Nature|November 17, 2016
Erratum: A renewed model of pancreatic cancer evolution based on genomic rearrangement patternsFaiyaz Notta, Michelle Chan-Seng-Yue, Mathieu Lemire, et al.
Pageof 7